Cell-Free Protein Expression Market Size To Rise USD 507.85 Mn By 2032

The global cell-free protein expression market size surpassed USD 232 million in 2022 and is projected to rise to USD 507.85 million by 2032, anticipated to grow at a CAGR of 8.2 percent during the projection period from 2023 to 2032.

Cell-Free Protein Expression Market Size and Growth Rate From 2023 To 2032

Market Overview

Cell-free protein expression (CFPE) is a method used in molecular biology and protein biochemistry to synthesize proteins outside of living cells. Unlike traditional protein expression systems that rely on living cells, CFPE systems operate in cell-free environments, allowing researchers to produce proteins in a controlled and customizable manner. This approach has several advantages, including rapid protein synthesis, simplified experimental conditions, and the ability to express toxic or difficult to express proteins.

In a typical cell-free protein expression system, the cellular machinery responsible for protein synthesis, including ribosomes, transfer RNAs (tRNAs), and aminoacyl-tRNA synthetases, is extracted from cells and incorporated into an in vitro reaction mixture. This mixture contains the necessary components for transcription and translation, such as DNA or mRNA templates, amino acids, energy sources, and cofactors.

Growth Factors

The global cell-free protein expression market is driven by several factors including the increasing prevalence of cancer and infectious disease, rising demand for recombinant proteins, drug discovery and developments, advancements in technology, expansion of synthetic biology and others. Furthermore, the growing product launches are expected to drive market growth over the forecast period.

  • For instance, in November 2023, the establishment of Lonza's novel GS Effex® cell line for the production of therapeutic antibodies with increased potency was disclosed. The GS Effex® cell line was created in response to urgent market demands brought on by the move toward increasingly complex therapeutic antibodies. GS Effex®, which is derived from Lonza's top-performing GS Xceed® cell line, integrates well with Lonza systems.
  • According to Cancer Australia, the probability of dying from cancer by the age of 85 is predicted to be 1 in 7 (or 15%) in 2022 (1 in 6 or 17% for men and 1 in 8 or 13% for women).
  • According to Cancer Research UK, by 2040, 28 million new instances of cancer are expected to occur globally year if incidence stays constant and population growth and ageing follow current patterns. This is a 54.9% rise from 2020, and it is anticipated that the growth in men will be greater than the increase in women (60.6% vs 48.8%).

Cell-Free Protein Expression Market Report Scope

Report Coverage Details
Market Revenue in 2023 USD 249.86 Million
Projected Forecast Revenue by 2032 USD 507.85 Million
Growth Rate from 2023 to 2032 CAGR of 8.2%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Regional Insights

North America is expected to capture the largest market share. The market growth in the region is attributed to the increasing prevalence of infectious diseases and increasing cases of cancer. For instance, according to the American Cancer Society Journals, lung cancer is the main cause of cancer mortality in the United States, accounting for about 350 fatalities per day out of 609,360 total cancer deaths and 1,918,030 new cases in 2022.

The incidence of female breast cancer continued to slowly climb, averaging 0.5% per year. Moreover, North America, particularly the United States, is a hub for biotechnology and pharmaceutical research. The country has a large number of academic and research institutions, biotech companies, and pharmaceutical firms that are actively engaged in protein expression studies. A demand for efficient and customizable protein expression systems, such as cell-free expression.

Furthermore, the availability of substantial research and development investments in the biotechnology and pharmaceutical sectors in the US contributes to advancements in protein expression technologies. Increased funding often supports the development and commercialization of innovative cell-free protein expression systems. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), in the U.S., biopharmaceutical companies invested more than any other industry in R&D in 2022, spending over $103 billion. Thus, this is expected to drive market growth in the region over the projected timeframe.

Market Dynamics


Growing investment

The R&D activities of proteomics and genomics in drug development are expanding due to the growth in funding made by various pharmaceutical and biopharmaceutical businesses. To address the growing demand for services, Thermofisher Scientific, for example, invested in spatial proteomics Ionpath company to scale up the MIBIscope equipment and provide end-to-end spatial proteomics services.

Furthermore, Protai was awarded USD 8 million in January 2022 to create an AI-based proteomics platform. This efficient method reduced R&D expenses and saved time, which enhanced the drug discovery process and accuracy. Proteomics and genomics have become more widely used as a result of these R&D efforts, which are also anticipated to fuel the market expansion.

Advancements in technology

Ongoing advancements in cell-free expression technologies, such as improvement in reaction conditions, increased protein yields, and enhanced scalability, contribute to the attractiveness of these systems. As technology improves, the efficiency and cost-effectiveness of cell-free protein expression may further drive market growth.


Limited adoption in routine protein production

Despite its advantages, cell-free protein expression has not been universally adopted for routine protein production. Researchers and industries may still prefer traditional cell-based expression systems for certain applications due to established protocols, familiarity, and the ability to handle a broader range of proteins. Thus, impacting the market growth over the anticipated timeframe.

High yield and scalability challenge

Achieving high protein yields and scalability for large scale production can be a challenge in cell-free expression systems. While these systems offer advantages in terms of rapid production, optimizing conditions for high yields on an industrial scale can be a complex task.


Growing utilization of advanced technology

To analyze and externally power the machinery of cellular protein creation, researchers must find new and creative approaches to provide better results in less time and money. Additionally, it helps produce proteins that could damage cells or require particular circumstances to fold properly. Because of its restricted use, the market for cell-free protein expression is still somewhat modest.

However, given the possibility of these technologies being extensively used, it is anticipated to rise significantly over the next few years. The potential of cell-free protein expression methods to transform the synthetic biology landscape through powerful in-vitro platforms seems highly promising. Recombinant protein production is now feasible due to the invention of a cell-free protein expression system, which represents a breakthrough in biomedical technology.

High throughput screening in drug discovery

The demand for high-throughput screening in drug discovery continues to grow. Cell-free protein expression’s ability to quickly produce proteins for screening purposes positions it as a valuable tool in the drug discovery process. The market has an opportunity to play a crucial role in accelerating drug development pipelines.

Recent Developments

  • In November 2023, the FDA approved a supplemental New Drug Application for XTANDI® (enzalutamide) as a result of the companies' participation in expedited development and review programs (Priority Review designation, Fast Track designation, Real-time Oncology Review), which were based on the Phase 3 EMBARK trial results. This was announced by Astellas Pharma Inc. and Pfizer Inc.
  • With its approval, XTANDI is now the only androgen receptor signaling inhibitor that the FDA has approved for use in treating patients with biochemical recurrence of high-risk BCR who have nonmetastatic castration-sensitive prostate cancer (nmCSPC). Gonadotropin-releasing hormone (GnRH) analog treatment may be used with XTANDI in patients with nmCSPC who have high-risk BCR.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • Takara Bio Company
  • Merck KGaA
  • New England Biolabs
  • Promega Corporation
  • Jena Bioscience GmbH
  • GeneCopoeia, Inc.
  • Biotechrabbit GmbH
  • Cube Biotech GmbH
  • CellFree Sciences Co., Ltd.

Market Segmentation

By Product

  • Expression Systems
    • E. coli Cell-free Protein Expression System
    • Wheat Germ Cell-free Protein Expression System
    • Rabbit Reticulocytes Cell-free Protein Expression System
    • Insect Cells Cell-free Protein Expression System
    • Human Cell-free Protein Expression System
    • Others
  • Reagents

By Application

  • Enzyme Engineering
  • High Throughput Production
  • Protein Labeling
  • Protein-Protein Interaction
  • Protein Purification

By Method

  • Transcription and translation systems
  • Translation systems

By End-User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Others

Buy this Research Report@ https://www.precedenceresearch.com/checkout/3329

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308